Icosavax discovers what caused its lead vaccine to flop, and doesn’t see it affecting follow-up programs

Seattle-based Icosavax was one of the companies in the rat race to develop Covid-19 vaccine shots better than Pfizer and Moderna. However, when clinical trials showed that its vaccine candidate, IVX-411, fared ‘below expectations,” the company launched an investigation. Now those results are out.

The problem, Icosavax says, had...

Click to view original post